WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO) held its first Quell® Wearable Pain Relief Technology™ user event last Thursday, April 27. As a customer-focused company, NeuroMetrix frequently looks to its users to inform product updates and innovation.
NeuroMetrix welcomed a group of 30 Quell users to its Waltham headquarters to “meet the makers,” learn about upcoming Quell product features, share their stories, and give feedback on the product. Quell users learned about product development directly from Shai N. Gozani, M.D., Ph.D., President and CEO at NeuroMetrix, and connected with peers and NeuroMetrix’s customer care, engineering, and marketing teams.
“We know that Governor Baker’s goal is to establish Massachusetts as a digital health hub and we are proud to contribute to that mission as a Massachusetts-based digital health company,” said Frank McGillin, Senior Vice President and Chief Commercial Officer at NeuroMetrix. “Many of those living with chronic pain in the Commonwealth have been reliant on medication to manage their day-to-day pain. Hearing that Quell has enabled many of the event’s attendees to reduce or eliminate their use of opioids was a rewarding experience. We look forward to hosting more of these events in the future.”
Attendees had the opportunity to share their experiences and discuss how Quell has changed their approach to pain management. "I did not know what it was like to live life without pain, until I got my Quell,” said one attendee. Another Quell user stated, “Quell has returned my freedom to choose what I want to do daily, not what my pain will let me do today. I have my life back again!"
While Quell provides an opportunity to reduce drug reliance, the reality is that many chronic pain sufferers will require some degree of continued usage of medications to deal with their pain. NeuroMetrix believes a “treatment toolbox” approach that looks to supplement pain medications with technology and other alternatives may be effective in many cases.
“There is no one-size-fits-all approach to treating chronic pain. Our goal is to provide a drug free treatment option to enhance the quality of life for those living with chronic pain,” said Dr. Gozani. “As a consumer health company, engaging our users is critical to achieving this goal. We were impressed by the response we received and will be applying this feedback to continue improving our product.”
Quell is designed for millions of people suffering from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell users can personalize and manage therapy discreetly via the Quell Relief app. Quell also offers advanced health tracking relevant to chronic pain sufferers including pain, sleep, activity, and gait. Quell was the winner of the 2016 SXSW (South by Southwest) Innovation Award for Best Wearable Technology. Quell is available at select healthcare professionals and retailers. Visit QuellRelief.com for more information.
NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit NeuroMetrix.com.